Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% ...

Immunovant, Inc.’s IMVT share price has dipped by 11.06%, which has investors questioning if this is right time to buy.

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Learn more about whether Alvotech or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which ...

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...

Immunovant (NASDAQ:IMVT – Free Report) had its price objective decreased by Bank of America from $38.00 to $33.00 in a ...

Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis (MG) and initial results from Period 1 of a mid-stage study of the ...

The dip came unexpectedly following the announcement of positive results from their respective studies on batoclimab for Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.